• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
GLP-1 RA prescription trends: January 2018 – June 2025

GLP-1 RA prescription trends: January 2018 – June 2025

by Truveta Research | Jul 24, 2025 | Research

Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and...
GLP-1 RA prescription trends: January 2018 – March 2025

GLP-1 RA prescription trends: January 2018 – March 2025

by Truveta Research | Apr 18, 2025 | Research, Research Insights

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in March 2025 increased relative to December 2024 (+12.96%). Anti-diabetic medication (ADM) prescribing increased from December 2024 to January 2025, then remained relatively stable until March...
Why women experience more GLP-1 side effects: New research from Olio Labs using Truveta Data

Why women experience more GLP-1 side effects: New research from Olio Labs using Truveta Data

by Truveta staff | Apr 1, 2025 | Research

GLP-1 drugs like Ozempic and Zepbound are transforming obesity treatment, yet 40-85% of patients are plagued by adverse GI events—particularly women. New research from Olio Labs, using Truveta Data, reveals that women experience nausea and vomiting at significantly...
GLP-1 RA prescription trends: January 2018 – December 2024

GLP-1 RA prescription trends: January 2018 – December 2024

by Truveta staff | Mar 7, 2025 | Research

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing rates in December 2024 were similar to those in September 2024 (-0.88%). Among ADMs,...
GLP-1 discontinuation and reinitiation trends study published in JAMA Network Open

GLP-1 discontinuation and reinitiation trends study published in JAMA Network Open

by Truveta staff | Jan 31, 2025 | Research

Discontinuation within one year was significantly higher in patients without T2D (64.8%) compared to those with T2D (46.5%). When patients experienced greater weight loss, they were less likely to discontinue the GLP-1 RA medications. Among patients with T2D, higher...
« Older Entries

Share this


Recent posts

  • Truveta experts: Biomarker testing trends in metastatic non-small cell lung cancer (NSCLC)
  • Multiple sclerosis: Real-world treatment patterns and outcomes
  • ISPE 2025: Real-world data survival patterns in glioblastoma patients

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.